Background. Age and gender may exert important influences on opioid responsiveness and chronic pain. These effects have not been explored in the setting of chronic intrathecal (IT) opioid therapy. The objective of this study was to evaluate the effect of age and sex on IT opioid requirements during the first year after implantation of an intrathecal drug delivery system (IDDS) in chronic noncancer pain patients.
Introduction
Opioid use in the management of chronic noncancer pain can be problematic [1] . In addition to known intrinsic opioid side effects such as constipation, sedation, and pruritus, tolerance to opioids often sets in, resulting in dose escalation [2] . Intrathecal (IT) infusion of opioids is utilized in refractory painful conditions when therapeutic efficacy of oral or transdermal opioids is limited by side effects [3, 4] . While the incidence of some opioid untoward effects, such as fatigue, cognitive deficits, and constipation, may be reduced with IT delivery, others are more common, such as pruritus and hypogonadism [5] . Escalating opioid doses have been described in noncancer pain with oral [6] [7] [8] as well as IT delivery [9] [10] [11] [12] [13] . While dose escalation in cancer-related pain is often due to disease progression [14] , in noncancer pain, it may be related to tolerance. Escalating doses of IT opiates have been associated with the occurrence of IT granulomas at the tip of IT catheters, with potential for neurologic compromise [15] [16] [17] [18] . In animal studies [19, 20] as well as in one retrospective clinical study [6] , age has been found to be an important determinant of oral opioid tolerance with older subjects being less likely to require dose escalation. The effect of age on opioid dose requirements in noncancer pain patients managed with intrathecal drug delivery systems (IDDSs) has not been explored. Additionally, gender-dependent changes in pain perception and opioid requirements have been described [21, 22] , but not in the setting of IT therapy.
In this study, the charts of patients implanted with IDDSs at one tertiary referral center between the years 2000 and 2006 were retrospectively reviewed. Opioid requirements and reported analgesic responses were analyzed over the first 12-month period after implantation with special emphasis on the effect of age. Additionally, genderdependent effects on IT opioid therapy were analyzed.
Methods

Study Population
Following Institutional Review Board approval for this study, the charts of all patients who received implanted IDDSs at the Cleveland Clinic Foundation by members of the Department of Pain Management between 2000 and 2006 were reviewed. This study is a primary analysis of the data collected during the first year postimplant. All patients implanted during this time frame (a total of 171 patients) were reviewed for inclusion in the study. This group comprised a variety of patients implanted for cancer-and noncancer-related pain as well as spasticity. Prior to implantation, a stepwise multidisciplinary approach was applied in the treatment and selection of these patients including appropriate psychological assessment, physical and occupational therapy as indicated, and conservative medical management including medication and minimally invasive interventions. To be included in the study, patients had to be implanted with IT pumps for delivery of opioids for the management of intractable noncancer pain. Exclusion criteria included cancer pain, IT baclofen for spasticity, and other IT agents used as a monotherapy or combination therapy (such as local anesthetics alone and/or ziconotide) in the absence of IT opioids. All patients included in the study had a successful IT trial using a continuous IT infusion in an inpatient setting prior to being implanted with the pump system. The agents used intrathecally included morphine sulfate, hydromorphone, or fentanyl either as single agents or in combination with other agents mostly bupivacaine or clonidine. The inpatient trial lasted a few days and was accomplished with continuous IT infusion through an externalized catheter and pump system. Oral opioids were replaced with a 24-hour IT opioid infusion dose that was equivalent to 50-100% of the oral dose, depending on the attending physician's preference. Oral opioids were discontinued once the IT infusion was started. The minimum possible infusion rate of the externalized pump was 0.1 mL/h, and patients were started at a rate of 0.2 mL/h and after at least 12 hours from initiation of this rate titrated slowly upwards as dictated by pain scores and clinical response to achieve greater than 50% pain relief. A total of eight physicians experienced in IT pump therapy contributed patients to this study.
Analyses
Data from patients were recorded for the first year postimplant. The parameters collected included age, sex, indication, pain scores on a 11-point numerical rating scale ([NRS], 0 = no pain and 10 = worse imaginable pain), oral opioid intake before and after implant, IT opioid dose, and IT medication type and rate. Charts were reviewed for pain intensity scores, before the IT pump trial as well as at 3, 6, and 12 months postimplant. Similarly, oral opioid consumption was recorded at baseline (trial date) and at 3, 6, and 12 months postimplant and was expressed in morphine equivalent daily dose (MEDD). IT opioids used in the selected patient population included morphine, hydromorphone, and fentanyl. Oral and IT opioid doses used were converted to morphine sulfate equivalent doses using accepted conversion ratios (morphine : hydromorphone : fentanyl, 100:20:1) [3] . To compare changes in IT opioid requirements over the first year postimplant, the dose amount was calculated as morphine dose equivalent and the rate of increase derived as a percentage of change over the baseline (implant time 0): Δ in % Current dose Baseline dose at implant Baseline op
The latter approach reflects changes in the rate of increase from baseline rather than comparing various absolute doses which vary significantly from patient to patient. To compare oral opioid consumption over the first year postimplant, the average MEDD in milligram was compared from implant time (time 0) to 3, 6, and 12 months postimplant. Changes in pain intensity scores are modeled with time as a covariate (as well as age and sex) taking into account the fact that observations for each patient are correlated to earlier time points (changes in the dosage for the same patient over time).
Statistical Analysis
The difference in pain scores and opioid dose (MEDD) between baseline (month 0) and each follow-up time point (i.e., month 3, 6, and 12), was examined by paired t-test. For the purpose of this analysis, age was examined as a dichotomous factor (patients <50 years old and patients >50 years old). The difference in dose and dose escalation (in percentage change over the baseline) between two age groups (age Յ50 vs age >50) at each time point (month 0, 3, 6, and 12) was compared using Kruskal-Wallis test within each cohort (male, female) as well as for the whole group (male + female). The data were summarized as mean and standard deviation (SD) of the mean and in chart presentation as mean and standard error of the mean. All tests were two-sided, and P values less than 0.05 were considered statistically significant.
Results
A total of 171 patients, all implanted consecutively with IDDSs, were identified. Of this population, 36 patients were excluded from our study analysis because 1) their indication for implant was cancer-related pain (13 patients); 2) they were treated only with baclofen infusion for spasticity (12 patients); or 3) their infused medication(s) did not include opioids (11 patients). The remaining 135 patients were included in the study, and all patients had IT opioid in their pumps throughout the 12-month period. Their demographics, including age, sex, indication for implant, average pain score at implant, oral opioid consumption, and IT initial dose at the time of implant are shown in Table 1 . The most common indication for patients to receive an implant was chronic pain postlumbar spinal surgery (also known as failed back surgery syndrome, overall 51.9%). This was followed by complex regional pain syndrome and spinal cord pathology (10.4% and 8.8%, respectively). A large group comprising 28.9% of the patients across age groups included various intractable pain syndromes such as postherpetic neuralgia, lumbosacral neuritis, visceral pain syndromes, osteoporosis pain, and diabetic neuropathy. The average patient age was 55.8 Ϯ 11.6 years old; 54.8% (74) were males and 45.2% (61) were females (Table 1) . Over the first 12 months following IDDS implant, pain scores improved significantly from 7.26 Ϯ 1.7 at baseline to 5.4 Ϯ 1.9 (P < 0.01, paired t-test, Table 1 ). Overall, there was a decrease in pain scores averaging 29.6 Ϯ 19.5% (P < 0.0001) at 12 months postimplant. The mean value of initial IT opioid dose administered was 1.89 Ϯ 1.9 mg/day, and this increased significantly at 12 months to 3.9 Ϯ 4.6 mg/day (P < 0.01, paired t-test, Table 1 ). Prior to undergoing an IT pump trial, the average oral opioid consumption in MEDD was 135.2 Ϯ 91 mg/day (n = 135) and at 12 months following implant, the dose did not seem to decrease significantly (112 Ϯ 106 mg/day). The most frequently used opioid medication at the initiation of the IDDSs was morphine, either as a single agent (59/135 patients) or in combination with bupivacaine (42/135 patients, Table 2 ). Other opioids used as single agents included hydromorphone (13/135) and fentanyl (3/135). The temporal pattern of various IT medications over the first 12 months of treatment is shown in Table 2 . Initially, 55.5% (75 out of 135) of the patients were initiated with monotherapy, 41.5% with combination of two agents (an opioid and a local anesthetic), and a small portion of 3% (four out of 135) was started with three agents (usually, a combination of an opioid with local anesthetic and clonidine or ziconotide). No difference was detected at onset of the IT therapy as 40 out of 85 patients were treated with Ն2 agents in the older group (47%) and 23 out 50 patients were treated with Ն2 agents in younger group (46%). At 12 months following pump implant, in the >50-year-old group, 40% of patients were receiving monotherapy and 51% were receiving dualagent therapy. On the other hand, in the <50-year-old group, 38% of patients were receiving monotherapy and 50% of patients were receiving dual-agent therapy. Hence, there was no difference in the proportion of patients using monotherapy or dual-agent combination therapy between the two studied age groups. The configuration of administered IT agents changed over time with a significant trend toward polypharmacy as shown in Table 2 . Three-agent therapy increased significantly from 3% at implant to almost 13% of the patient population at 12 months postimplant. The most common additions as a third agent to the current medication infused were clonidine and ziconotide.
Age-dependent Outcome Comparison Analysis of IT Therapy
The effect of age on IT opioid requirements over the first year postimplant was analyzed by stratifying the patient population as younger adults (from 18-50 years old) and older adults (over 50 years old). The average patient age was 41.6 Ϯ 5.5 (n = 50) in the Յ50-year-old group and 64 Ϯ 11 years in the >50-year-old group (n = 85; Table 3 ). When dichotomous (separate groups for >50 and Յ50 years old) analysis is performed, a similar significant decrease in pain score in both younger and older patient 28.9% (n = 39)
Oral opioids dose at time of implant (MEDD in mean Ϯ SD mg/day) Baseline 135 Ϯ 91 12 months postimplant 112 Ϯ 106 Intrathecal morphine dose at implant (ME mean Ϯ SD in mg/day) Baseline 1.84 Ϯ 1.9 12 months postimplant 3.9 Ϯ 2.95* * Significant difference from baseline. Data are expressed as mean Ϯ SD, or number (percentage). SD = standard deviation; NRS = numerical rating scale pain score; MEDD = morphine equivalent daily dose; ME = intrathecal morphine equivalent.
populations is noted (Table 3 and Figure 1 ). A paired t-test between baseline and follow-up intervals indicated that there is significant pain relief at 3, 6, and 12 months following IDDS implantation ( Figure 1 ). For both groups, pain scores decreased from baseline to follow-up, and no significant difference is noted between groups. Of note, pain scores do not continue to decline beyond 3 months; they rather appear to level off. An analysis of patients who reported >50% pain relief by NRS scores was performed.
As shown on Table 3 , there is a significant number of patients with >50% pain relief in the older patient population, with 25% of patients in that group meeting the criteria of >50% NRS reduction vs 10% in the younger patient population (Table 3) . . NRS = Numerical rating scale (pain score); NS = not significant between the two populations; MEDD = morphine equivalent daily dose; ME = intrathecal morphine equivalent; ER visits = emergency room visit during the first year postimplant.
To examine whether pain relief was time, age, or indication dependent, pain scores were modeled with time, age, and indication used as covariates in a mixed model correlating each patient's postimplant pain score to his or her baseline score. No significant effects on pain scores due to age (P = 0.527, n = 135) or indication (P = 0.19, n = 135) were observed and only time since initiation of IT therapy was correlated with decreases in pain scores (P < 0.001, n = 135).
The rate of increase in IT opioid medications during the first 12 months after implant was determined using changes in percentage of the IT daily opioid dose compared with baseline (implant, time 0). The baseline dose of IT opioids infused at implant in the younger patient group was 2.1 Ϯ 2.3 mg/day (n = 50) and was not significantly different from that in the older patient group, which was 1.65 Ϯ 2.1 mg/day (n = 85; Table 3 ). As demonstrated in Figure 2 , a gradual increase in IT opioids is observed, reaching a peak at 12 months for both groups of patients. In younger patients (Յ50 years old), the dose of IT opioids increased significantly at all time points compared with baseline (402 Ϯ 267% at 3 months, 679 Ϯ 381% at 6 months, and 750 Ϯ 450% at 12 months). Patients >50 years old had a more tempered IT opioid dose increase over the first year postimplant compared with baseline (86 Ϯ 31% at 3 months, 148 Ϯ 46% at 6 months, and 195 Ϯ 85% at 12 months [P < 0.005, n = 85]). Within Figure 1 Pain response using the numerical rating scale (NRS) vs time since implant in months (m) in >50-year-old and <50-year-old patient age groups. Data are presented as mean Ϯ SE. * and † denote significant difference from time 0 in older and younger patient groups, respectively.
Figure 2
Intrathecal dose escalation rate during the first 12 months postimplant in younger and older patients. The rate of increase of intrathecal opioids is significantly higher in the younger patient population when compared with the patient population over 50 years of age. An age-dependent effect was observed as early as 6 months but significant at 6 and 12 months (* different from the other age group at the same time point). Each data point represents the percentage change over the baseline (D in % as mean Ϯ SD).
groups, the dose increase is significantly different at all time points (3, 6, and 12 months) in the younger patient population (P < 0.001, n = 50, one-way analysis of variance [ANOVA]) and is significantly different at 6 and 12 months compared with baseline in the >50-year-old group (P < 0.01, n = 85). While receiving similar doses of IT opioids at baseline, there is a significant difference between the younger and older population groups in the rate of increase in IT opioid doses at 12 months postimplant (P < 0.01). As shown in Figure 2 and Table 3 , the rate of increase of IT opioids is significantly higher in the younger patient population when compared with the patient population over 50 years of age.
In Figure 3 ). Figure 3 demonstrates that supplemental oral opioids in younger patients did not change significantly from baseline through 12 months postimplant. Older patients not only showed a significant decrease in oral opioid consumption compared with baseline but also expended a significantly lower MEDD when compared with younger patients, 62 Ϯ 49 vs 105 Ϯ 140 mg/day at 12-month postimplant (mean Ϯ SD, two-tailed independent t-test P < 0.007, n = 55 and 85, respectively).
Gender-dependent Outcome Comparison Analysis of IT Therapy
Gender-and age-dependent outcomes were also analyzed, and the data are summarized in Table 4 . As indicated, there is significant decrease in pain scores in women from 7.4 Ϯ 2.1 at baseline (mean Ϯ SD) to 5.8 Ϯ 2.7 at 12 months, P < 0.001. A similar decrease is observed also in men from 7.1 Ϯ 2.3 at baseline to 5.6 Ϯ 2.1 at 12 months (P < 0.001 paired t-test). The number of males that had >50% decrease in NRS scores at 12 months postimplant was 17 (23%) vs nine females or 14.7%, P < 0.01. Oral opioid intake in females was 158 Ϯ 123 mg at baseline and did not decrease significantly at 12 months postimplant (126 Ϯ 138 mg;
Figure 3
Changes in oral opioid consumption. Supplemental oral opioids in younger patients did not change significantly from baseline through 12 months postimplant. Older patients not only showed a significant decrease in oral opioid consumption compared to baseline but also expended a significantly lower morphine equivalent daily dose when compared to younger patients. The dose of oral opioids at 12 months following intrathecal drug delivery systems implant is expressed as mg of morphine equivalent daily dose (mean Ϯ SE).
( † Significant change from baseline for the >50 age group; ‡ significant change between groups).
paired t-test, two-tailed P value = 0.1789). On the other hand, oral opioid intake in men decreased significantly from 138 Ϯ 99.7 at baseline to 79 Ϯ 89 (P < 0.01, paired t-test) at 12 months postimplant. Furthermore, the absolute amount of oral MEDD in females was significantly higher than in males at 12 months postimplant (126 Ϯ 138 mg vs 79 Ϯ 89 mg, two-tailed P < 0.001).
IT opioid dose at implant was not significantly different at baseline in males (1.85 Ϯ 2.6 mg/day) vs females (1.35 Ϯ 2.1 mg/day). At 12 months postimplant, the dose increased significantly from baseline to 3.1 Ϯ 4.9 in males and 3.59 Ϯ 4.9 in females (P = 0.56, independent t-test). Additionally, the rate of dose increase expressed as a percentage increase over the baseline is not different in males vs females at 12 months postimplant (mean Ϯ standard error, 270 Ϯ 73% in males vs 600 Ϯ 450% in females, independent t-test, two-tailed P = 0.35).
Discussion
The results of this study suggest that age may be an important consideration for patients contemplating IT therapy for noncancer pain. Considering age as an outcome variable, the results of the current study suggest that IT opioid requirements are significantly higher in patients less than 50 years of age compared with those over 50 years old. Furthermore, daily oral opioid consumption postimplant is significantly decreased in comparison to preimplant usage only in the older patient population. While the proportion of patients using more than one IT agent increased during the 1-year follow-up in this study, there was no significant difference between both age groups in the number or proportion of patients who received monotherapy or combination IT therapy in this study. No apparent significant gender-specific sensitivity to IT opioid therapy is observed, but oral opioid consumption subsequent to IDDS implant was significantly higher in females in this study. The overall improvement in analgesia noted in this report is congruent with previous studies on the effectiveness of opioid IT therapy [9, 13, [23] [24] [25] [26] . The average reduction in pain scores in this study, though significant, is of lesser magnitude than some previous studies [24, 25] . Differences in patient population age, sex, and indication might account for this variance, although the results are in line with the only prospective study on IT therapy [23] .
There have been only few retrospective opioid studies that considered age as a factor in patients with chronic cancer or noncancer pain receiving oral opioids [6, 21, 22] . The results are somewhat contradictory in two studies of cancer pain patients. Vigano et al. reported that the elderly experience similar pain intensity but require significantly smaller amount of opioids analgesia [21] . In this study, age was examined as a dichotomous variable (<75 and >75 years old) as well as a categorical variable (<65, 65-74, and >75 years old). Their analysis was based on opioid consumption during the 7-14 days of admission in a palliative care unit rather than long-term administration.
On the other hand, Mercadante et al. contradicted the notion that older patients are more susceptible than younger adults to the opioid effects [22] . They reported that the opioid escalation index (calculated as dose at stabilization -dose at admission/days) was no different between the younger and older patient population [22] . Their results were based on analysis of the differences between three groups of patients: group I under 65 years old; group II, 65-75 years; and group III, over 75 years old. However, there are significant limitations to this study including limited duration of follow-up and limited number of patients (e.g., group 3 was only comprised of 10 patients, which would not allow for any significant analysis). In fact, a limitation of both studies [21, 22] includes the short duration of titration and follow-up (days) of the patients which may be related to the clinical setting of these studies in a cancer pain population. A long-term assessment of opioid therapy was performed by BuntinMushock et al. [6] in noncancer pain patients over a 2-year period. In this study, older patients (Ն60 years old) had a more tempered increase in oral opioid consumption compared with younger individuals (Յ50 years old). Additionally, younger patients with non-neuropathic pain appeared to escalate opioid dosing at a significantly higher rate during the first year but more importantly without apparent benefit, as there were no significant changes in pain intensity scores in response to opioids in that subgroup of patients [6] .
While almost all previous studies documented an increase in IT opioid dosage with time [9, 10, 12, 13, [27] [28] [29] , there has been only one retrospective clinical study that examined the effects of age on IT opioid requirements [30] . The average patient age in IT opioid studies varied with the study, most having an average age in the early 50s (56 Ϯ 0.7 [9] , 46.1 Ϯ 12 [23] , 54 Ϯ 11.2 [13] , 53.4 [27] , and 54 [12] ). Some opioid studies took into consideration the type of pain experienced by patients receiving opioids (nociceptive vs neuropathic and some included visceral and deafferentation pain) with varied results [6, 9, 13] , some suggesting a better response in patients with neuropathic pain [6, 9] while others reporting better relief of nociceptive pain with IT opioids [13] . These studies stratified patients as having neuropathic or nociceptive pain based on diagnoses or symptom characteristics of pain. However, such methodology for classification of pain types may not accurately reflect underlying pathophysiologic processes [31] and a substantial bulk of patients requiring IT therapy (failed back syndrome patients) have a complex combination of nociceptive and neuropathic contribution to their pain symptoms. We made no attempt to subdivide patients based on the type of pain in the current noncancer pain study given similar distribution of diagnoses across age groups as well as the inherent difficulties of assigning patients' pain as nociceptive or neuropathic.
In our study, both age groups had similar reduction in pain scores with the peak of pain relief achieved at 3 months postimplant (Figure 1) , and that level of relief did not appear to change significantly at 12 months. This finding has been reported by others and may be related to tolerance [29] . However, other factors may explain the apparent leveling off of analgesic response. These may include the complexities of chronic pain pathophysiology and sensitization, the limited targets and limited effectiveness of currently applied IT medications, as well as psychosocial variables, among others. Additionally, there was no gender-related difference in the effectiveness of IT opioids (with DNRS as the primary outcome measure).
Dominguez et al. examined retrospectively the predictive value of IT opioids trial dose as well as age and gender for long-term therapy by dividing the patient population into three groups, depending on the single intrathecal morphine bolus dose-response at trial time: low (0.25 mg), standard (0.5 mg), and high (1 mg) [30] . They found out that the level of trial dose effectiveness might have some predictive value as far as opioid requirements and dose escalation. Furthermore, they reported lower analgesic requirements for women consistently during the entire treatment period compared with men as well as lower IT analgesic requirements in patients over 65 years old [30] . A significant confounding factor, as the study authors' state, was the lack of reporting of other systemic opioid consumption during the same treatment period as well as lack of treatment effectiveness data to correlate with IT dose escalation. This could complicate the interpretation of the results and conclusions. Historically, IT opioids replaced systemic opioids that patients were on prior to IDDS implant. Starting with higher IT opioid dose requirements, however, predisposes to higher IT opioid dose escalation [30] . This has led to a recent trend for weaning off systemic opioids prior to IDDS trial and implant. There have been anecdotal reports (though none published) of lower opioid requirements and lesser opioid dose escalation in these patients. However, this strategy may not be practical for all patients, including patients with cancerrelated pain and patients who refuse to wean off oral opioids prior to IDDS consideration. Nonetheless, this strategy deserves consideration and further study especially in younger patients with intractable noncancer pain.
The impact of aging on analgesic requirements has been studied in animals [19, 20, [32] [33] [34] as well as in humans [6, 21, 22, 35] . Several modulating factors could influence IT opioid requirements including:
1. Age-dependent change in nociception that may require dose adjustment in opioids [36] [37] [38] [39] . Extensive human studies have found significant age-dependent changes in nociceptive thresholds [40, 41] . Furthermore, there may be significant behavioral and psychological determinants of pain reporting in older patients (such as reasoning that pain is a sensation that has to be endured) that may potentially influence opioid dose requirements in this population [35, 42] . 2. Physicians' caution in delivering higher doses of opioids (including IT opioids) to older patients. This, however, did not appear to be the case in the current study as preimplant average oral opioid doses were similar in both age groups. 3. Disease progression, while often a feature of cancerrelated pain, is not usually a factor in noncancer pain or postlumbar laminectomy syndrome, would not be expected to occur at a slower rate in the patient population over 50, and would not explain differential opioid requirements between older and younger patients in this study. 4. Tolerance development: The rate of IT opioid dose escalation during the first year postimplant in the younger patient group is about threefold that of the older patient group. IT opioids increase continuously at all time points postimplant in both younger and older patients, however consistently at a faster pace in the younger patient group (Figure 2 ). This suggests that IT opioid dose escalation phenomena become established early on and are more robust in younger patients receiving IT opioids. As opposed to the older patient group that showed gradual decline in oral opioid consumption, the younger patient group had an initial drop followed by a gradual increase of oral opioids ( Figure 3 ). This differential oral opioid consumption between younger and older patients also suggests tolerance development in younger patients. Tolerance is defined as a state of adaptation in which exposure to a drug induces changes that result in a decrease of the drug's effects over time [43] . The cellular and molecular mechanisms of opioid tolerance remain elusive. Proposed mechanisms include the activation of neuroinflammation and excitatory amino acid receptors [44] ; opioid receptor modifications, i.e., downregulation of opioid receptors and opioid receptor trafficking [45] ; receptor G-protein uncoupling [33, 46] ; protein kinase C translocation [32] ; and adaptation of spinal/ supraspinal neuronal network signaling [47] . Recently, there has been an increased focus on the role of microglia generally in chronic neuropathic pain mechanisms and particularly in opioid tolerance development [48] . Nonetheless, a thorough understanding of opioid tolerance mechanisms in human subjects is currently lacking despite the phenomenon being well established. In a retrospective study of 120 patients with chronic noncancer pain with an average follow-up of 3.4 years, Winkelmuller and Winkelmuller [13] reported the development of tolerance in seven patients after an average treatment of 4-6 months with IT opioids. These authors did not provide a definition for IT tolerance in their study and did not specify the ages of the tolerant patients. Age-related changes in opioid tolerance may help explain the differential effects of age on opioid requirements observed in our study; 5. Opioid-induced hyperalgesia (OIH) may also be a modulating factor that could influence IT opioid requirements. Recent evidence indicates that there is significant overlap between tolerance and opioid induced hyperalgesia and that indeed the same phenomenon might underlie both processes [43, 44, 49] .
Our study suggests that, and not unlike oral opioid consumption, patients suffering from chronic noncancer pain are subject to significant increases in opioid requirements over time. This increase is much more prominent in younger patients. However, unlike oral opioid consumption, IT granulomas can develop the tip of IT catheters, a unique and serious complication to high-dose IT opiate administration [16, 18] . Hence, practitioners should heed more caution in implanting younger chronic noncancer pain patients with IT opiate drug delivery systems. It should be noted, however, that this study is limited by its retrospective nature, the concomitant use of other interventions, and the lack of information regarding other types of oral pharmacological agents used (such as nonsteroidal anti-inflammatory drugs, membrane stabilizers, and antidepressants). Furthermore, functional outcome assessments of IT therapy are lacking, as the only outcome measure available was the pain intensity scores as reported by patients. Another limitation is that patients were implanted and managed by eight practitioners experienced in IT pump therapy. Decisions about which IT medications were used and their titrations were performed by the individual physician (usually the implanter) involved in the care of the patient. Nonetheless, practice parameters were fairly similar among attending physicians within the Department of Pain Management. For instance, titration of IT medications was done in a standard fashion in increments of 10-20% as dictated by patient's clinical status and perception of pain relief.
While it appears that women may require greater oral opioid maintenance doses, they do not seem to require higher doses of IT opioids. Gender differences may exist in the experience of pain [50, 51] as well as in the analgesic response to opioid agonists, with females being more sensitive than males to k-opioid agonists [52] . The clinical significance of gender differences noted in our study is unclear, and a larger sample size may be necessary to confirm a gender-related difference in opioid requirements in patients implanted with IT pain pumps.
In summation, an age-dependent escalation in IT opioid requirements is evident in patients with chronic noncancer pain implanted with IT pumps. Younger patients increase their IT opioid doses at a much higher rate than older patients. As such, younger patients with chronic noncancer pain may be less amenable to IT opioid therapy and may also require supplemental oral opioids concomitant with higher IT dosing needs. Greater caution should be exercised when screening younger patients with chronic noncancer pain for IT opiate therapy. Nevertheless, prospective clinical research studies are necessary to elucidate clinically relevant age and gender differences in pharmacokinetics and pharmacodynamics of IT opioid therapy.
